Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline July 23, 2024
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline July 23, 2024
BRG01 Enters Ph 2 Clinical Trial For Solid Tumors On Recurrent/Metastatic Nasopharyngeal Carcinoma July 23, 2024
Darolutamide meets primary endpoint in Ph 3 ARANOTE trial in men with metastatic hormone-sensitive prostate cancer July 23, 2024
EMA validated Type II Application for Opdivo plus Yervoy for 1L Treatment of Unresectable or Advanced HCC July 23, 2024
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations for Evaluating ORIC-944 + AR Inhibitors for the Treatment of Prostate Cancer July 23, 2024
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations July 23, 2024
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors July 23, 2024
CatalYm Announces New Financing of $150M to Support Broad Ph 2b Development Program for Visugromab July 23, 2024
RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study July 23, 2024
FAILED TRIAL: Ph 3 TiNivo-2 didn’t meet primary endpoint from rechallenging RCC patients with immunotherapy after receiving ICI beyond progression on previous ICIs July 23, 2024
U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric AML July 23, 2024
End-of-Phase-2 Meeting Outcomes and Topline Interim Ph 2 Data for BOT/BAL in MSS Colorectal Cancer announced July 23, 2024
